Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap Up – Time to Buy?

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG)’s share price gapped up before the market opened on Wednesday . The stock had previously closed at $18.37, but opened at $19.31. Ascentage Pharma Group International shares last traded at $19.2060, with a volume of 409 shares traded.

Wall Street Analysts Forecast Growth

Several research firms recently commented on AAPG. Deutsche Bank Aktiengesellschaft began coverage on Ascentage Pharma Group International in a report on Friday, April 24th. They issued a “buy” rating and a $40.00 target price on the stock. BTIG Research reaffirmed a “buy” rating and set a $48.00 price target on shares of Ascentage Pharma Group International in a report on Monday, June 15th. Raymond James Financial reaffirmed a “buy” rating on shares of Ascentage Pharma Group International in a research report on Wednesday, June 10th. China Intl Cap upgraded Ascentage Pharma Group International to a “strong-buy” rating in a report on Monday, April 6th. Finally, B. Riley Financial began coverage on Ascentage Pharma Group International in a research report on Wednesday, June 10th. They set a “buy” rating and a $45.00 target price on the stock. Two research analysts have rated the stock with a Strong Buy rating and eight have assigned a Buy rating to the company’s stock. According to data from MarketBeat.com, Ascentage Pharma Group International currently has a consensus rating of “Buy” and a consensus price target of $46.43.

Ascentage Pharma Group International Stock Up 0.7%

The firm’s fifty day moving average price is $18.65 and its 200-day moving average price is $22.54. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.79 and a quick ratio of 1.77.

Institutional Investors Weigh In On Ascentage Pharma Group International

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Hsbc Holdings PLC purchased a new position in shares of Ascentage Pharma Group International during the second quarter worth about $391,000. UBS Group AG lifted its holdings in shares of Ascentage Pharma Group International by 149.4% in the 3rd quarter. UBS Group AG now owns 18,345 shares of the company’s stock valued at $716,000 after purchasing an additional 10,988 shares during the last quarter. Finally, Citadel Advisors LLC purchased a new stake in shares of Ascentage Pharma Group International in the 3rd quarter valued at about $383,000.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.